Thus, pharmacological inhibition of p110δ or genetic inactivation of the catalytic activity of either p110γ or p110δ reduces IL-17 levels and/or numbers of IL-17-producing T cells in mouse models of asthma [16], psoriasis [17], or multiple sclerosis [18]. The gene discussed is IL17A; the disease is multiple sclerosis.